Icatibant Hikma (Icatibant)

Icatibant is a bradykinin B2 receptor antagonist used to manage hereditary angioedema attacks.

• Hereditary angioedema type I: rapidly reduces swelling and associated pain.
• Hereditary angioedema type II: alleviates acute episodes of edema.
• Hereditary angioedema with normal C1‑INH: provides symptom control during attacks.

• Icatibant competitively blocks the bradykinin B2 receptor on vascular endothelial cells, preventing bradykinin‑mediated vasodilation and increased vascular permeability. By inhibiting this pathway, the drug curtails the cascade that leads to the rapid swelling characteristic of hereditary angioedema, thereby restoring normal vascular tone and fluid balance during an acute attack.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects

• Injection site pain: discomfort at the site of subcutaneous administration.
• Redness or erythema: localized skin irritation.
• Swelling at injection site: mild to moderate edema.
• Nausea: transient gastrointestinal upset.
• Headache: mild to moderate intensity.
• Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

• Hypersensitivity reaction: rash, itching, or hives.
• Anaphylaxis: severe, potentially life‑threatening allergic response.
• Severe hypotension: marked drop in blood pressure.
• Airway angioedema: swelling that may compromise breathing.
• Thrombocytopenia: low platelet count observed in rare cases.

Before using Icatibant, clinicians should consider several safety measures.

• Verify diagnosis: confirm hereditary angioedema type before administration.
• Assess allergy history: avoid in patients with known hypersensitivity to icatibant.
• Monitor for reactions: observe for signs of hypersensitivity during and after injection.
• Caution with ACE inhibitors: increased bradykinin levels may augment adverse effects.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that influence the bradykinin pathway or cardiovascular status.

Major Interactions (Avoid)

• ACE inhibitors: may increase bradykinin levels and heighten risk of angioedema.
• Other bradykinin B2 antagonists: concurrent use can lead to unpredictable pharmacodynamics.

Moderate Interactions (Monitor Closely)

• Neprilysin inhibitors: potential additive effect on bradykinin activity.
• Diuretics: may affect blood pressure response; monitor hemodynamics.